Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $175.00 short call and a strike $180.00 long call offers a potential 19.9% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $175.00 by expiration. The full premium credit of $0.83 would be kept by the premium seller. The risk of $4.17 would be incurred if the stock rose above the $180.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 66.92 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
3 Dividend Stocks You May Be Overlooking
Sun, 09 Jul 2017 15:41:00 +0000
Why Cisco Systems, Taiwan Semiconductor Manufacturing Co., and Amgen are dividend stocks you shouldn't ignore.
Two cancer drug prices have already been hiked by 8% this year
Sat, 08 Jul 2017 14:44:21 +0000
The move provides fodder “for those who argue drug companies raise prices ‘because they can,’” an analyst said.
Better Buy: Amgen Inc. vs. Celgene Corporation
Sat, 08 Jul 2017 11:27:00 +0000
Which big biotech stock wins in a head-to-head matchup between Amgen and Celgene?
Is Amgen Making a Mistake?
Fri, 07 Jul 2017 17:58:00 +0000
Yesterday, Celgene (CELG) bought the rights to an anti-cancer treatment from Beigene, making it the latest company to bet big on what's known as a PD-1 inhibitor. Bristol-Myers Squibb (BMY) and Merck (MRK) are the leaders in this field but it's Amgen (AMGN) that's notably absent. Thus, for companies who have decided to invest heavily in the I/O space like Celgene, Regeneron Pharmaceuticals (REGN) (and others), it makes more sense to own both components of a combination rather than give much of the value away to the PD(L)1 owner.
Improving Health for This Pharma ETF
Fri, 07 Jul 2017 16:00:00 +0000
This pharma ETF could be ready to become a healthcare leader.
Related Posts
Also on Market Tamer…
Follow Us on Facebook